Nebula Research & Development’s CRISPR Therapeutics CRSP Stock Holding History

Nebula Research & Development’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,148	Closed	-$1.22M	–	217
2025 Q2	$1.22M	Buy	25,148 +7,469	+42%	+$289K	0.1%	332
2025 Q1	$602K	Buy	+17,679	New	+$749K	0.06%	551
2024 Q1	–	Sell	-25,065	Closed	-$1.57M	–	781
2023 Q4	$1.57M	Buy	+25,065	New	+$1.39M	0.47%	15
2023 Q3	–	Sell	-5,013	Closed	-$281K	–	526
2023 Q2	$281K	Buy	+5,013	New	+$284K	0.21%	221

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Nebula Research & Development's CRSP Position: Q3 2025 in Review

Nebula Research & Development sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 25,148 shares — an estimated $1.22M sold.

Nebula Research & Development first reported a position in CRSP in Q2 2023 and held it in 4 quarters. The position peaked at $1.57M in Q4 2023. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

Nebula Research & Development reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
Nebula Research & Development sold 25,148 CRISPR Therapeutics shares in Q3 2025, an estimated $1.22M.
Nebula Research & Development first reported a position in CRISPR Therapeutics in Q2 2023 and held it in 4 quarters.
Nebula Research & Development's CRISPR Therapeutics position peaked at $1.57M in Q4 2023.
440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.